$IPA

ImmunoPrecise Antibodies Ltd

  • NASDAQ

PRICE

$5.3 -

Extented Hours

VOLUME

9,035

DAY RANGE

5.0762 - 5.5

52 WEEK

3.51 - 8.1

Join Discuss about IPA with like-minded investors

profile
@marketjay #Market Assassin Corp
recently

those were good continuation set ups, some names that I was looking at for this morning but have not developed a full report yet were IPA, BLZE, CB, JPM, MMM, MELI, EQIX, SIDU, SGTX

80 Replies 12 👍 15 🔥

SO
@soheil.n #StockTraders.NET
recently

only got $IPA

130 Replies 15 👍 7 🔥

SO
@soheil.n #StockTraders.NET
recently

watchlist: $AEHR, $WISA, $IGC, $IPA - all 2nd red days hopefully some shove on these as they've gone further down than i wanted them to.....hot ticker of the day: $ALZN

145 Replies 9 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

watch tomorrow: $sckt, $NRXP, $IPA, $WISA $CEMI

42 Replies 10 👍 12 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

what a day with $igc $ipa and $cemi

41 Replies 6 👍 8 🔥

profile
@maletone #StockTraders.NET
recently

please halt down $IPA

96 Replies 12 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

longed small $IPA

135 Replies 14 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

wish I longed $IPA

118 Replies 6 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

$IPA will be on watch tomorrow

147 Replies 7 👍 10 🔥

profile
@dros #droscrew
recently

Downgrades 2/9: $BILI $CRHM $CUB $ENR $ESPR $GLUU $HUYA $IPA $IPHI $KBH $LADR $MAA $MANT $MTDR $OCGN $PBA

124 Replies 7 👍 8 🔥

profile
@dros #droscrew
recently

ideally an IPA though

79 Replies 13 👍 14 🔥

Key Metrics

Market Cap

136.92 M

Beta

0.69

Avg. Volume

17.25 K

Shares Outstanding

24.84 M

Yield

0%

Public Float

0

Next Earnings Date

2022-09-08

Next Dividend Date

Company Information

IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company's therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.

Website:

HQ: 4464 Markham St Unit 3204 Victoria, V8Z 7X8 British Columbia

Related News